Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Interferons (IFNs) are utilized in hepatocellular carcinoma (HCC) treatment due to their antiviral and immune-stimulatory properties.
• Signal transducer and activator of transcription 1 (STAT1) is crucial for IFN signaling, with its function dependent on phosphorylation.
• The distinct roles of phosphorylated (p-STAT1) and unphosphorylated (u-STAT1) forms in HCC remain unclear.

Purpose of the Study:

• To elucidate the differential functions of p-STAT1 and u-STAT1 in HCC.
• To investigate the impact of STAT1 phosphorylation states on HCC cell proliferation and response to IFN therapy.

Main Methods:

• Analysis of STAT1 expression and localization in HCC tumor tissues.
• Assessment of cell cycle arrest and growth inhibition upon manipulation of STAT1 phosphorylation.
• Evaluation of interferon-stimulated gene (ISG) induction by p-STAT1 and u-STAT1.
• Investigation of HCC cell sensitivity to IFN treatment following targeted blocking of u-STAT1 or p-STAT1 induction.

Main Results:

• u-STAT1 is significantly elevated and cytoplasmically localized in HCC tissues, correlating with cell cycle progression and growth.
• p-STAT1 is largely absent in HCC tissues; its induction by IFN-α triggers ISGs but has a moderate impact on HCC cell growth.
• Both u-STAT1 and p-STAT1 are induced by IFN-α via distinct time-dependent pathways, mediating different ISG expression patterns.
• Blocking u-STAT1 induction, but not p-STAT1, sensitizes HCC cells to IFN treatment.

Conclusions:

• u-STAT1 promotes HCC cell proliferation, whereas p-STAT1 exhibits inhibitory effects on HCC growth.
• STAT1 phosphorylation state critically regulates HCC cell responsiveness to IFN therapy.
• Targeting STAT1 phosphorylation dynamics offers a potential strategy to enhance IFN-based treatments for HCC.